ZBTB20
Basic information
Region (hg38): 3:114314500-115147292
Previous symbols: [ "ZNF288" ]
Links
Phenotypes
GenCC
Source:
- Primrose syndrome (Definitive), mode of inheritance: AD
- diabetes mellitus (Strong), mode of inheritance: AD
- Primrose syndrome (Strong), mode of inheritance: AD
- Primrose syndrome (Moderate), mode of inheritance: AD
- Primrose syndrome (Strong), mode of inheritance: AD
Clinical Genomic Database
Source:
Condition | Inheritance | Intervention Categories | Intervention/Rationale | Manifestation Categories | References |
---|---|---|---|---|---|
Primrose syndrome | AD | General | Genetic knowledge may be beneficial related to issues such as selection of optimal supportive care, informed medical decision-making, prognostic considerations, and avoidance of unnecessary testing | Craniofacial; Dermatologic; Musculoskeletal; Neurologic | 25062845; 25017102; 27061120; 30256248 |
ClinVar
This is a list of variants' phenotypes submitted to
- not provided (11 variants)
- Primrose syndrome (8 variants)
- Inborn genetic diseases (4 variants)
- Intellectual disability (2 variants)
Variants pathogenicity by type
Statistics on ClinVar variants can assist in determining whether a specific variant type in the ZBTB20 gene is commonly pathogenic or not.
In the table, we include only reliable ClinVar variants with their consequences to MANE Select, Mane Plus Clinical transcripts, or transcripts with TSL equals 1. Click the count to view the source variants.
Warning: slight differences between displayed counts and the number of variants in ClinVar may occur, primarily due to (1) the application of a different transcript and/or consequence by our variant effect predictor or (2) differences in clinical significance: we classify Benign/Likely benign variants as Likely benign and Pathogenic/Likely pathogenic variants as Likely pathogenic.
Variant type | Pathogenic | Likely pathogenic | VUS | Likely benign | Benign | Sum |
---|---|---|---|---|---|---|
synonymous | 80 | 85 | ||||
missense | 15 | 22 | 82 | 18 | 142 | |
nonsense | 6 | |||||
start loss | 0 | |||||
frameshift | 11 | |||||
inframe indel | 1 | |||||
splice donor/acceptor (+/-2bp) | 3 | |||||
splice region | 2 | 2 | ||||
non coding | 15 | |||||
Total | 21 | 30 | 91 | 105 | 16 |
Variants in ZBTB20
This is a list of pathogenic ClinVar variants found in the ZBTB20 region.
You can filter this list by clicking the number of variants in the Variants pathogenicity by type table.
Position | Type | Phenotype | Significance | ClinVar |
---|---|---|---|---|
3-114338999-T-C | not specified | Benign (Jul 17, 2020) | ||
3-114339010-C-T | - | no classification for the single variant (-) | ||
3-114339032-G-A | Primrose syndrome • ZBTB20-related disorder | Benign/Likely benign (Jan 22, 2024) | ||
3-114339039-T-C | Uncertain significance (Mar 04, 2022) | |||
3-114339049-C-T | Uncertain significance (May 03, 2023) | |||
3-114339064-T-C | Uncertain significance (May 01, 2024) | |||
3-114339076-C-T | Likely benign (Sep 01, 2022) | |||
3-114339077-G-A | Likely benign (Oct 13, 2023) | |||
3-114339077-G-C | ZBTB20-related disorder | Likely benign (Nov 08, 2022) | ||
3-114339095-C-T | Likely benign (Apr 22, 2023) | |||
3-114339102-G-A | Uncertain significance (Aug 14, 2023) | |||
3-114339113-C-G | Likely benign (Jan 15, 2023) | |||
3-114339115-C-T | Uncertain significance (Sep 27, 2023) | |||
3-114339117-C-A | Primrose syndrome | Uncertain significance (Dec 11, 2023) | ||
3-114339120-G-A | Uncertain significance (May 26, 2022) | |||
3-114339132-C-G | Uncertain significance (Apr 14, 2022) | |||
3-114339132-C-T | Uncertain significance (Jun 23, 2022) | |||
3-114339133-G-A | Uncertain significance (Mar 01, 2022) | |||
3-114339137-A-C | Likely benign (Oct 03, 2023) | |||
3-114339141-G-A | Primrose syndrome • Inborn genetic diseases • ZBTB20-related disorder | Conflicting classifications of pathogenicity (Dec 20, 2023) | ||
3-114339151-C-T | Likely benign (Oct 03, 2023) | |||
3-114339153-G-A | not specified • ZBTB20-related disorder | Benign (Dec 18, 2023) | ||
3-114339155-A-AG | Primrose syndrome | Uncertain significance (Mar 27, 2019) | ||
3-114339158-G-A | Likely benign (Sep 03, 2023) | |||
3-114339161-G-T | Benign/Likely benign (Jul 01, 2024) |
GnomAD
Source:
Gene | Type | Bio Type | Transcript | Coding Exons | Length |
---|---|---|---|---|---|
ZBTB20 | protein_coding | protein_coding | ENST00000474710 | 4 | 809178 |
pLI Probability LOF Intolerant | pRec Probability LOF Recessive | Individuals with no LOFs | Individuals with Homozygous LOFs | Individuals with Heterozygous LOFs | Defined | p |
---|---|---|---|---|---|---|
0.974 | 0.0262 | 125743 | 0 | 3 | 125746 | 0.0000119 |
Z-Score | Observed | Expected | Observed/Expected | Mutation Rate | Total Possible in Transcript | |
---|---|---|---|---|---|---|
Missense | 4.27 | 217 | 481 | 0.452 | 0.0000335 | 4859 |
Missense in Polyphen | 67 | 241.18 | 0.27781 | 2262 | ||
Synonymous | 1.12 | 201 | 222 | 0.904 | 0.0000183 | 1493 |
Loss of Function | 4.02 | 3 | 24.4 | 0.123 | 0.00000115 | 268 |
LoF frequencies by population
Ethnicity | Sum of pLOFs | p |
---|---|---|
African & African-American | 0.00 | 0.00 |
Ashkenazi Jewish | 0.00 | 0.00 |
East Asian | 0.0000550 | 0.0000544 |
Finnish | 0.0000462 | 0.0000462 |
European (Non-Finnish) | 0.00000954 | 0.00000879 |
Middle Eastern | 0.0000550 | 0.0000544 |
South Asian | 0.00 | 0.00 |
Other | 0.00 | 0.00 |
dbNSFP
Source:
- Function
- FUNCTION: May be a transcription factor that may be involved in hematopoiesis, oncogenesis, and immune responses (PubMed:11352661). Plays a role in postnatal myogenesis, may be involved in the regulation of satellite cells self-renewal (By similarity). {ECO:0000250|UniProtKB:Q8K0L9, ECO:0000269|PubMed:11352661}.;
- Disease
- DISEASE: Primrose syndrome (PRIMS) [MIM:259050]: A disease characterized by macrocephaly, intellectual disability, disturbed behavior, dysmorphic facial features, ectopic calcifications, large calcified ear auricles, and progressive muscle wasting. {ECO:0000269|PubMed:25017102}. Note=The disease is caused by mutations affecting the gene represented in this entry.;
Recessive Scores
- pRec
- 0.151
Intolerance Scores
- loftool
- rvis_EVS
- 0.35
- rvis_percentile_EVS
- 74.49
Haploinsufficiency Scores
- pHI
- 0.822
- hipred
- Y
- hipred_score
- 0.673
- ghis
Essentials
- essential_gene_CRISPR
- N
- essential_gene_CRISPR2
- N
- essential_gene_gene_trap
- N
- gene_indispensability_pred
- E
- gene_indispensability_score
- 0.998
Gene Damage Prediction
All | Recessive | Dominant | |
---|---|---|---|
Mendelian | Medium | Medium | Medium |
Primary Immunodeficiency | Medium | Medium | Medium |
Cancer | Medium | Medium | Medium |
Mouse Genome Informatics
- Gene name
- Zbtb20
- Phenotype
- hematopoietic system phenotype; cardiovascular system phenotype (the observable morphological and physiological characteristics of the mammalian heart, blood vessels, or circulatory system that are manifested through development and lifespan); mortality/aging (the observable characteristics related to the ability of a mammalian organism to live and age that are manifested throughout development and life span); behavior/neurological phenotype (the observable actions or reactions of mammalian organisms that are manifested through development and lifespan); immune system phenotype; vision/eye phenotype; muscle phenotype; nervous system phenotype (the observable morphological and physiological characteristics of the extensive, intricate network of electochemical structures in the body that is comprised of the brain, spinal cord, nerves, ganglia and parts of the receptor organs that are manifested through development and lifespan); growth/size/body region phenotype; integument phenotype (the observable morphological and physiological characteristics of the skin and its associated structures, such as the hair, nails, sweat glands, sebaceous glands and other secretory glands that are manifested through development and lifespan); homeostasis/metabolism phenotype; cellular phenotype;
Gene ontology
- Biological process
- negative regulation of transcription by RNA polymerase II;positive regulation of interferon-beta production;positive regulation of interleukin-6 production;positive regulation of tumor necrosis factor production;positive regulation of glycolytic process;positive regulation of lipid biosynthetic process;lipid homeostasis;cellular response to glucose stimulus
- Cellular component
- nucleus;nucleoplasm;cytoplasm;nuclear body
- Molecular function
- DNA-binding transcription factor activity, RNA polymerase II-specific;DNA-binding transcription repressor activity, RNA polymerase II-specific;transcription regulatory region DNA binding;metal ion binding